Dr. Kari L. Kendra
Claim this profileOhio State University Comprehensive Cancer Center
Area of expertise
Melanoma
Kari L. Kendra has run 7 trials for Melanoma. Some of their research focus areas include:
Cutaneous Melanoma
Kari L. Kendra has run 5 trials for Cutaneous Melanoma. Some of their research focus areas include:
Affiliated Hospitals
Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital And Solove Research Institute At Ohio State University Medical Center
Clinical Trials Kari L. Kendra is currently running
Dabrafenib + Trametinib Access
for Cancer
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Recruiting
3 awards
Phase 4
2 criteria
Encorafenib/Binimetinib/Nivolumab vs Ipilimumab/Nivolumab
for Melanoma
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.
Recruiting
1 award
Phase 2
23 criteria
More about Kari L. Kendra
Clinical Trial Related
8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Kari L. Kendra has experience with
- Natural Killer Cell Therapy
- Temozolomide
- Selinexor
- Nivolumab
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
Breakdown of trials Kari L. Kendra has run
Melanoma
Cutaneous Melanoma
Skin Cancer
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kari L. Kendra specialize in?
Kari L. Kendra focuses on Melanoma and Cutaneous Melanoma. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Kari L. Kendra currently recruiting for clinical trials?
Yes, Kari L. Kendra is currently recruiting for 3 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Kari L. Kendra has studied deeply?
Yes, Kari L. Kendra has studied treatments such as Natural Killer Cell Therapy, Temozolomide, Selinexor.
What is the best way to schedule an appointment with Kari L. Kendra?
Apply for one of the trials that Kari L. Kendra is conducting.
What is the office address of Kari L. Kendra?
The office of Kari L. Kendra is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.